Q1 2024 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2024-05-15 · accession 0001104659-24-061747
$197.9M
Reported value
5
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $93.3M | 47.2% | 4,038,842 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $39.5M | 19.9% | 1,849,947 | Common | SOLE |
| 49705R105 | KNTEUSD | Kinnate Biopharma Inc. | $25.7M | 13.0% | 9,671,643 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals, Inc. | $20.8M | 10.5% | 875,000 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $18.6M | 9.38% | 8,325,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.